TY - JOUR
AB - Reactions 1704, p301 - 2 Jun 2018 Haemoptysis: case report A 64-year-old man died of massive haemoptysis during treatment with pembrolizumab for stage-IVb lung adenocarcinoma [route not stated]. The man was scheduled to receive treatment with pembrolizumab 200mg every 21 days. rd On 3 November, the first dose of pembrolizumab was administered without any immediate side effects. His social history was significant for smoking and had no previous episodes of haemoptysis. On day 15, he developed massive haemoptysis and died. Author comment: "As the tumor was NSCLC strongly positive PD-L1, firstline pembrolizumab, a 200-mg flat dose every 21 days, was scheduled . . . The achievement of a great response and shrinkage in centrally located lung tumors with vascular involvement may be not so uncommon in strongly PDL1–positive NSCLC when pembrolizumab is used in the first-line setting. Therefore, the risk for severe bleeding may be a real concern." Artal-Cortes A, et al. Massive Hemoptysis after the First Administration of Pembrolizumab in a Strongly Positive, Centrally Located NSCLC. Journal of Thoracic Oncology 13: e76-e77, No. 5, May 2018. Available from: URL: http:// doi.org/10.1016/j.jtho.2017.12.004 - Spain 803323731 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 
TI - Pembrolizumab
JF - Reactions Weekly
DO - 10.1007/s40278-018-46944-2
DA - 2018-06-02
UR - https://www.deepdyve.com/lp/springer-journals/pembrolizumab-2ZTnP6Xg6G
SP - 301
EP - 301
VL - 1704
IS - 1
DP - DeepDyve
ER -